Smart investments, healthy returns

Capital Cell is the world’s leading alternative investment platform for early-stage biotech and life science companies. Selected by experts, backed by visionaries, we give you the chance to shape the future of health, one investment at a time. 

Performance to date

93,5%
Successful
rounds

101,6M€
Total amount
invested

115
Campaigns
completed


Platform authorized and supervised by the National Securities Market Commission (CNMV).

ESMA License (European Securities and Markets Authority).

69 days remaining
Target
€1.200.000
Invested
46.2%
63,7% Committed

Hemerion

flag

Hemerion develops unique light-based therapies to extend and save lives of cancer patients.

64 days remaining
Target
€500.000
Invested
73.4%
74,5% Committed

MSInsight

flag

MSInsight utilizes cutting-edge DNA sequencing to deliver highly accurate cancer tests, ensuring precise diagnoses and tailored treatments.

64 days remaining
Target
€1.000.000
Invested
42.7%
43,3% Committed

Biointaxis

Biointaxis develops and brings to market gene therapies for neurological diseases.

64 days remaining
Target
€300.000
Invested
65.0%
72,5% Committed

Dipneo

The first CPR ventilation device suitable for all types of users in out-of-hospital cardiac arrest situations.

8 days remaining
Target
€500.000
Invested
100.1%
105,7% Committed

Improfit.AI

B2B SaaS solutions providing AI-powered computer vision tools for digitizing rehabilitation.

81 days remaining
Target
€2.000.000
Invested
54.9%
64,4% Committed

Pharmamel

Development of new melatonin-based drugs for sepsis, inflammatory, and viral diseases.

15 days remaining
Target
€575.000
Invested
109.0%
114,9% Committed

Spinally

Introducing FuturaLead: The miniaturized spinal cord implant for a pain-free life.

49 days remaining
Target
€500.000
Invested
96.9%
99,8% Committed

Open Stent Solution

flag

Your support extends beyond funding a device; it catalyzes a transformative shift in healthcare.

Successfully closed!
Target
€600.000
Invested
133.1%

Flomics

Flomics is developing a liquid biopsy test that can detect cancer even before the first symptoms appear, everything out of a blood sample.

Successfully closed!
Target
€1.000.000
Invested
106.3%

Oncoheroes Biosciences Inc.

The world's first biotech company dedicated exclusively to developing drugs for pediatric cancer.

Successfully closed!
Target
€400.000
Invested
105.8%

MOWOOT 2024

Innovative, non-invasive, non-drug solution for bowel dysfunction (BD)

Successfully closed!
Target
€800.000
Invested
140.6%

NUUBO 2024

Biotech investments: equity funding yields global impact

Capital Cell funds companies at the cutting edge of science, developing diagnostics, treatments and tools that will transform the future of healthcare.

Through our expert network of over 3,500 industry professionals, each investment opportunity allows you to have a profound impact on the global health of the future. Only 3% of the companies that approach Capital Cell are selected to be funded on our platform, each chosen for its potential to scale globally and the opportunity to earn exceptional returns.

Invest alongside the best science, investment, and social impact institutions.

Lead the health revolution.

For investors

Learn how our smart investments offer you healthy returns.

For life sciences and biotechnology companies

Learn how we support companies seeking investment and our criteria for selection.

Our network of experts

experts are members of the
BioExpert Network

companies have been reviewed
by our experts

BioExpert Network, the independent network of experts

The cornerstone of our evaluation process is the BioExpert Network (BEN), a community of over 3,500 experts in life sciences, health, biotechnology and medicine. The collective wisdom of these highly qualified professionals ensures that only the best biotech investment opportunities make it to our platform.

Alira Health, consulting in health and innovation

Every company that launches a campaign with Capital Cell goes through a thorough maturity assessment with Alira Health, who check that the company understands the regulatory and market access needs and is well prepared at this stage for the coming investment rounds.

Elion, intellectual property
agency

More than 30 institutions and companies already trust Elion for their intellectual property managament, including CSIC, GMV Aerospace & Defence, Tecnalia, Verisure, Sword Health, Venvirotech and the Universities of Liverpool, Complutense de Madrid, Malaga and Galway. 

Success stories we're proud of

Bionure - now Accure Therapeutics - raised €1,200,000 in 2017 and €1,337,000 in 2019 to develop an innovative multiple sclerosis drug.

Vytrus went public through an IPO, giving investors a success with its innovative production of plant cell cultures.

GoodGut's diagnostic and therapeutic technology for digestive diseases continues development and commercialization after its sale to HIPRA.